The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin

Journal of Clinical and Aesthetic Dermatology

Volumn 4, Issue 9, 2011, Pages

  Del Rosso, James Q ^a,b,c   Levin, Jacquelyn ^d  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c Las Vegas Skin & Cancer Clinics Ltd   (United States)

^d Largo Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYL PEROXIDE; CALCITRIOL; CATHELICIDIN; CLOBETASOL; DEFENSIN; DESMOCOLLIN; DESMOGLEIN 1; FILAGGRIN; PROTEIN DESMOCOLLIN 1; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RETINOIC ACID; RETINOID; UNCLASSIFIED DRUG;

ACNE VULGARIS; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; CELL DAMAGE; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; IMMUNE RESPONSE; KERATINOCYTE; LIPID COMPOSITION; LIPID MEMBRANE; NONHUMAN; PERMEABILITY BARRIER; PSORIASIS; REVIEW; ROSACEA; SKIN CARE; SKIN FUNCTION; SKIN STRUCTURE; SKIN WATER LOSS; STRATUM CORNEUM; XEROSIS;

EID: 80755156455     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Kligman AM. A brief history of how the dead stratum corneum became alive. In: Elias PM, Feingold KR, eds. Skin Barrier. New York: Taylor & Francis; 2006:15-24.
2. Elias PM. The epidermal permeability barrier: from Saran Wrap to biosensor. In: Elias PM, Feingold KR, eds. Skin Barrier. New York: Taylor & Francis; 2006:25-32.
3. Proksch E, Elias PM. Epidermal barrier in atopic dermatitis. In: Bieber T, Leung DYM, eds. Atopic Dermatitis. New York: Marcel Dekker; 2002:123-143.
4. Del Rosso JQ. Understanding skin cleansers and moisturizers: the correlation of formulation science with the art of clinical use. Cosmet Dermatol. 2003;16:19-31.
5. DiNardo A, Wertz PW. Atopic dermatitis. In: Leyden JJ, Rawlings AV, eds. Skin Moisturization, 1st ed. New York: Marcel Dekker; 2002:165-178.
6. Harding CR. The stratum corneum: structure and function in health and disease. Dermatol Ther. 2004;17:6-15.
7. Yamamoto A, Serizawa S, Ito M, et al. Stratum corneum abnormalities in atopic dermatitis. Arch Dermatol Res. 1991;283:219- 223.
8. Cook M, Danby S, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129:1892-1908.
9. Ogawa H, Yoshiike TJ. A speculative view of atopic dermatitis: barrier dysfunction in pathogenesis. Dermatol Sci. 1993;5:197-204. (Pubitemid 23265478)
10. Dirschka T, Tronnier H, Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141. (Pubitemid 38932283)
11. Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol. 2008;1(1):20-25.
12. Draelos, ZD. Concepts in skin care maintenance. Cutis. 2005;76(6 Suppl):19-25. (Pubitemid 43094510)
13. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17(suppl 1):26-34.
14. Del Rosso JQ. The use of moisturizers as an integral component of topical therapy for rosacea: clinical results based on the assessment of skin characteristics study. Cutis. 2009;84:72-76.
15. Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4(11):771-778.
16. Misra M, Ananthapadmanabhan KP, Hoyberg K, et al. Correlation between surfactant-induced ultrastructural changes in epidermis and transepidermal water loss. J Soc Cosmet Chem. 1997;48:219-234.
17. Rawlings AW, Watkinson A, Rogers J, Mayo HJ, Scott IR. Abnormalities in stratum corneum structure, lipid composition, and desmosome degradation in soap-induced winter xerosis. J Soc Cosmet Chem. 1994;45:203-220.
18. Rawlings AV, Scott IR, Harding CR, Bowser PA. Stratum corneum moisturization at the molecular level. J Invest Dermatol. 1994;103(5):731-740. (Pubitemid 24350145)
19. Menon GK, Norlen L. Stratum corneum ceramides and their role in skin barrier function. In: Leyden J, Rawlings A, eds. Skin Moisturization. New York, NY: Marcel Dekker, Inc.; 2002:31-60.
20. Bouwstra JA, de Graaff A, Gooris GS, et al. Water distribution and related morphology in human stratum corneum at different hydration levels. J Invest Dermatol. 2003:120:750-758. (Pubitemid 36529073)
21. Kligman AM. Biology of the stratum corneum. In: Montagna W, ed. The Epidermis. New York: Academic Press Inc.; 1964.
22. Elias PM. Physiologic lipids for barrier repair in dermatology. In: Draelos ZD, ed. Cosmeceuticals, 1st ed. Philadelphia: Elsevier- Saunders; 2005:63-70.
23. Koch PJ, Roop DR, Zhou Z. Cornified envelope and corneocyte-lipid envelope. In: Elias PM, Feingold KR, eds. Skin Barrier. New York: Taylor & Francis; 2006:97-110.
24. Tetsuji H. Cornified envelope. In: Rawlings AV, Leyden JJ, eds. Skin Moisturization, 2nd ed. New York: Informa Healthcare; 2009:83-97.
25. Haftek M, Simon M, Serre G. Corneodesmosomes: pivotal actors in stratum corneum adhesion and desquamation. In: Elias PM, Feingold KR. Skin Barrier. New York: Taylor & Francis; 2006:171-189.
26. Imokawa G, Abe A, Higaki Y, et al. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol. 1991;96:523-526.
27. Elias PM, Feingold KR. Stratum corneum barrier function: definitions and broad concepts. In: Elias PM, Feingold KR. Skin Barrier. New York: Taylor & Francis; 2006:1-3.
28. Braff M, DiNardo A, Gallo R. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol. 2005;124:94-400.
29. Elias P. Stratum corneum defensive functions: an integrated view. J Invest Dermatol. 2005;5:183-200. (Pubitemid 41648149)
30. Schroder JM, Harder J. Antimicrobial skin peptides and proteins. Cell Mol Life Sci. 2006;63:469-486.
31. Elias PM, Feingold KM. Permeability barrier homeostasis. In: Elias PM, Feingold KR. Skin Barrier. New York: Taylor & Francis; 2006:337-361.
32. O'Regan GM, Irvine AD. The role of filaggrin in the atopic diathesis. Clin Exp Allergy. 2010:40:965-972.
33. Scott IR, Harding CR. Barrett JG. Histidine rich proteins of the keratohyaline granules: source of the free amino acids, urocanic acid and pyrolidone carboxylic acid in the SC. Biochem Biophys Acta. 1982:719;110-111.
34. Katagiri C, Sato J, Nomura J, et al. Changes in environmental humidity affect the water-holding property of the stratum corneum and its free amino acid content, and the expression of filaggrin in the epidermis of hairless mice. J Dermatol Sci. 2003;31:29-35. (Pubitemid 36286956)
35. Mao-Qiang M, Brown BE, Wu-Pong S, et al. Exogenous nonphysiologic vs. physiologic lipids: divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol. 1995;131:809-816.
36. Elias PM, Ansel JC, Woods LD, et al. Signaling networks in barrier homeostasis: the mystery widens. Arch Dermatol. 1996;132:1505-1506. (Pubitemid 26424553)
37. McLean I. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol. 2008;128:2117-2119. (Pubitemid 352001213)
38. Choi MJ, Maibach HI. Role of ceramides in barrier function of healthy and diseased skin. Am J Clin Dermatol. 2005;6:215-223. (Pubitemid 41159408)
39. Imokawa G. Ceramides as natural moisturizing factors and their efficacy in dry skin. In: Leyden JJ, Rawlings AV, eds. Skin Moisturization, 1st ed. New York: Marcel Dekker; 2002:267-302.
40. Del Rosso JQ. Moisturizers: function, formulation, and clinical applications. In: Draelos ZD. Cosmeceuticals. Philadelphia: Saunders Elsevier; 2009:97-102.
41. James WD, Berger TG, Elston DM. Skin: basic structure and function. In: James WD, Berger TG, Elston DM, eds. Andrews' Diseases of the Skin, 10th ed. Philadelphia: Saunders-Elsevier; 2006:1¬13.
42. Johnson AW. Cosmeceuticals: function and the skin barrier. In: Draelos ZD. Cosmeceuticals. Philadelphia: Saunders-Elsevier; 2009:7-14.
43. Cork MJ, Moustafa M, Danby S, et al. Skin barrier dysfunction in atopic dermatitis. In: Rawlings AV, Leyden JJ, eds. Skin Moisurization, 2nd ed. New York: Informa Health; 2009:211-239.
44. Fluhr JW, Darlenski R. Skin barrier. In: Revuz J, et al., eds. Life Threatening Dermatoses and Emergencies in Dermatology. Heidelberg, Germany: Springer-Verlag; 2009:3-18.
45. Elias PM, Woods LD, Feingold KR. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat. 1999;10:119-126. (Pubitemid 29416060)
46. Jungersted JM, Hogh JK, Hellgren LI, et al. Ethnicity and stratum corneum ceramides. Br J Dermatol. 2010;163:1169-1173.
47. DiNardo A, Wetz P, Giannetti A, et al. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol. 1998;78:27-30. (Pubitemid 28103674)
48. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121: 1337-1343.
49. Leung DYM. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic disease. J Allergy Clin Immunol. 1995;96: 302-319.
50. Rawlings AV, Canestrari DA, Dobkowski B. Moisturizer technology versus clinical performance. Dermatol Ther. 2004;17:49-56.
51. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47:198-208.
52. Lucky AW, Leach AD, Laskarzewski P, et al. Use of an emollient as a steroid sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997;14:321-324. (Pubitemid 27332923)
53. Hanifin JM, Hebert AA, Mays SR, et al. Effects of a low-potency corticosteroid formulation plus a moisturizing regimen in the treatment of atopic dermatitis. Curr Therapeutic Res. 1998;59:227-233. (Pubitemid 28206661)
54. Boguniewicz M. Conventional topical treatment of atopic dermatitis. In: Bieber T, Leung DYM, eds. Atopic Dermatitis. New York: Marcel Dekker; 2002:453-477.
55. Draelos ZD. The effect of ceramide-containing skin care products on eczema resolution duration. Cutis. 2008; 81:87-91.
56. Zettersten EM, Ghadially R, Feingold KR, et al. Optimal ratios of topical stratum corneum lipids improve barrier recovery in chronologically aged skin. J Am Acad Dermatol. 1997;37:403-408. (Pubitemid 27430637)
57. Frankel A, Sohn A, Patel RV, Lebwohl M. Bilateral comparison study of pimecrolimus 1% cream and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis. J Drugs Dermatol. 2011;10(6):666.
58. Levin J, Miller R. A guide to the ingredients and potential benefits of over-the-counter cleansers and moisturizers for rosacea patients. J Clin Aesthet Dermatol. 2011;4(8):31-49.
59. Levin J, Maibach H. Human buffering capacity considerations in the elderly. In: Farage M, Miller K, Maibach HI, eds. Textbook of Aging Skin. Berlin: Springer-Verlag; 2010:139-145.
60. Hachem JP, Man MQ, Crumrine D, et al. Sustained serine protease activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J Invest Dermatol. 2005;125:510-520.
61. Levin J, Maibach HI. Human skin buffering capacity: overview. In: Zhai H, Wilhelm KP, Maibach HI, eds. Marzulli and Maibach's Dermatotoxicology, 7th ed. Boca Raton: CRC Press, Taylor and Francis Group; 2008:971-980.
62. Caspers PJ, Lucassen GW, Carter EA, et al. In-vivo confocal Raman microspectroscopy of the skin: noninvasive determination of molecular concentration profiles. J Invest Dermatol. 2001;116:434-442. (Pubitemid 32202909)
63. Rawlings AV, et al. Dry and xerotic skin conditions, In: Leyden JJ, Rawlings AV, eds. Skin Moisturization, 1st ed. New York: Marcel Dekker, Inc.; 2002:119-143.
64. Ananthapadmanabhan KP, Moore DJ, Subramanyan K, et al. Cleansing without compromise: the impact of cleansers on the skin barrier and the technology of mild cleanser. Dermatol Ther. 2004;17:16-25.
65. Ananthapadmanabhan KP, Yang L, Vincent C, et al. A new technology in mild and moisturizing cleansing liquids. Cosmetic Dermatol. 2009;22(6):307-316.
66. Sparsa A, Boulinguez S, Le Brun V, et al. Acquired ichthyosis with pravastatin. J Eur Acad Dermatol Venereol. 2007;21:549-550.
67. Schmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on barrier function. Skin Pharmacol Physiol. 2006;19:296-302. (Pubitemid 44808083)
68. Behne MJ. Epidermal pH. In: Rawlings AV, Leyden JJ, eds. Skin Moisturization, 2nd ed. New York: Informa Healthcare; 2009:125-148; 163-180.
69. DiNardo A, Gallo RL. Cutaneous barriers in defense against microbial invasion. In: Elias PM, Feingold KR. Skin Barrier. New York: Taylor & Francis; 2006:363-377.
70. Eissa A, Diamandis EP. Kallikrein-related peptidases: an emerging family of pivotal players in epidermal desquamation and barrier function. In: Rawlings AV, Leyden JJ, eds. Skin Moisturization, 2nd ed. New York: Informa Healthcare; 2009:125-148.
71. Lee SH, Jeong SK, Ahn SK. An update of the defensive barrier function of skin. Yonsei Medical Journal. 2006;47(3):293-306. (Pubitemid 43984155)
72. Nagy I, Kemeny L. Skin immune system. In: Revuz J, et al., eds. Life Threatening Dermatoses and Emergencies in Dermatology. Heidelberg, Germany: Springer-Verlag; 2009:19-28.
73. Ghadially R. Psoriasis and ichthyosis. In: Leyden JJ, Rawlings AV, eds. Skin Moisturization, 1st ed. New York: Marcel Dekker; 2002:165-178.
74. Frohm M, Agerberth B, Ahangari G, et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem. 1997;272:15258-15263. (Pubitemid 27255544)
75. Schauber J, Dorschner RA, Coda AB, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117:803-811. (Pubitemid 46348539)
76. Biao L, Elias PM, Feingold KR. The role of the primary cytokines, TNK, IL-1, IL-6, in permeability barrier homeostasis. In: Elias PM, Feingold KR. Skin Barrier. New York: Taylor & Francis; 2006:305-318.
77. Thiele JJ. The epidermal antioxidant barrier. In: Elias PM, Feingold KR, eds. Skin Barrier. New York: Taylor & Francis; 2006:379-397.
78. Bieber T, Prolss J. Atopic dermatitis. In: Gaspari AA, Tyring SK, eds. Clinical and Basic Immunodermatology. London, Springer- Verlag; 2008:193-206.
79. Wuthrich B, Schmid-Grendelmeier P. Definition and diagnosis of intrinsic versus extrinsic atopic dermatitis. Conventional topical treatment of atopic dermatitis. In: Bieber T, Leung DYM, eds. Atopic Dermatitis. New York: Marcel Dekker; 2002:1-20.
80. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh). 1980;92(Suppl):44-47.
81. Diepgen TL, Fartsch M, Hornstein OP. Evaluation and relevance of atopic basic and minor features in patients with atopic dermatitis and in the general population. Acta Derm Venereol (Stockh). 1989;144:50-54. (Pubitemid 19228714)
82. Williams HC, Pembrokle AC, Burney PGF, et al. Community validation of the UK Working Party's diagnostic criteria for atopic dermatitis. Br J Dermatol. 1996;135:12-17. (Pubitemid 26225107)
83. Schultz Larsen F, Diepgen T, Svensonn A. Clinical criteria in diagnosing AD: the Lillehammer criteria 1994. Acta Derm Venereol (Stockh). 1996;76(Suppl 196):115-119.
84. Leyden JJ, Marples RR, Kligman AM. Staphylococcal aureus in the lesions of atopic dermatitis. Br J Dermatol. 1974;90:525- 530.
85. Leung DYM. The role of Staphylococcus aureus in atopic dermatitis. In: Bieber T, Leung DYM, Eds. Atopic Dermatitis, 1st ed. New York: Marcel Dekker; 2002:401-418.
86. Seidenari S, Giusti G. Objective measurement of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol. 1995;75:429-433. (Pubitemid 26051887)
87. Schafer L, Kragballe K. Abnormalities in epidermal lipid metabolism in 11 patients with atopic dermatitis. J Invest Dermatol. 1991;96:10-15.
88. Irvine AD, McClean WHI. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol. 2006;126:1200-1202. (Pubitemid 43997892)
89. Uitto J, McGrath JA. The role of fliaggrin in skin disease. In: Rawlings AV, Leyden JJ, eds. Skin Moisturization, 2nd ed. New York: Informa Health; 2009:57-67.
90. Fallon PG, Sasaki T, Sandilands A, et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genetic. 2009;41:602-608.
91. Martin DB, Gaspari AA. Toll-like receptors In: Gaspari AA, Tyring SK, eds. Clinical and Basic Immunodermatology. London: Springer-Verlag; 2008:67-84.
92. Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K, et al. The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J All Clin Immunol. 2004;113:565-567. (Pubitemid 38338967)
93. Zdolsek HA, Jenmalm MC. Reduced levels of soluble CD14 in atopic children. Clin Exp Allergy. 2004:34:532-539. (Pubitemid 38534883)
94. Rothenbacher D, Weyermann M, Beermann C, Brenner H. Breastfeeding, soluble CD14 concentration in breast milk and risk of atopic dermatitis and asthma in early childhood: birth cohort study. Clin Exp Allergy. 2005:35;1014-1021. (Pubitemid 41603134)
95. Jalian HR, Kim J. Antimicrobial peptides. In: Gaspari AA, Tyring SK, eds. Clinical and Basic Immunodermatology. London: Springer-Verlag; 2008:131-145.
96. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151-1160.
97. de Jongh GJ, Zeeuwen PL, Kucharekova M, et al. High expression levels of keratinocyte antimicrobial peptides in psoriasis compared with atopic dermatitis. J Invest Dermatol. 2005;125(6):1163-1173.
98. Howell MD, Wollenberg A, Gallo RL, et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Immunol. 2006;117(4):836-841.
99. Leung D. Infection in atopic dermatitis. Curr Opin Pediatr. 2003;15(4):399-404. (Pubitemid 37006350)
100. Werfel T, Heeg, K, Neumaier M, et al. R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol. 2004;113(3):565-567. (Pubitemid 38338967)
101. Morath S, Geyer A, Hartung T. Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med. 2001;193:393-398.
102. Yamamoto A, Takenouchi, Ito M. Impaired water barrier function in acne vulgaris. Arch Dermatol Res. 1985;287:214-218.
103. Weber ST, Thiele JJ, Han N, et al. Topical alpha-tocotrienol supplementation inhibits lipid peroxidation but fails to mitigate increased transepidermal water loss after benzoyl peroxide treatment to human skin. Free Radical Biol Med. 2003;34(2):170-176. (Pubitemid 36084321)
104. Draelos ZD, Ertel KD, Berge CA. Facilitating facial retinization through barrier improvement. Cutis. 2006;78:275-281. (Pubitemid 44720416)
105. Elewski BE, Fleischer AB, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea. Arch Dermatol. 2003;139:1444-1450. (Pubitemid 37433134)
106. Torok HM. Rosacea skin care. Cutis. 2000;66(4 Suppl):14-16.
107. Lonne-Rahm SB, Fischer T, Berg M. Stinging and rosacea. Acta Derm Venereol (Stockh). 1999;79: 460-461.
108. Nestle FO. Psoriasis. In: Gaspari AA, Tyring SK, eds. Clinical and Basic Immunodermatology. London: Springer-Verlag; 2008:207-216.
109. Motta S. Abnormality of water barrier function in psoriasis: role of ceramide fractions. Arch Dermatol. 1994;130(4):452-456. (Pubitemid 24123365)
110. Ghadially R, Reed JT, Elias EM. Stratum corneum structure and function correlates with phenotype in psoriasis. J Invest Dermatol. 1996;107(4):558-564. (Pubitemid 26338579)
111. Schroeder WT. Type 1 keratinocyte transglutaminase: expression inn human skin and psoriasis. J Invest Dermatol. 1992;99(1):27-34.
112. Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005;53:850-858.
113. Kao JS, Fluhr JW, Man MQ, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120:456-464. (Pubitemid 36298433)
114. Hong SP, Oh Y, Jung M, et al. Topical calcitriol repairs epidermal permeability and antimicrobial barriers induced by corticosteroids. Br J Dermatol. 2010;162: 1251-1260.
115. Tabata N, O'Goshi K, Zhen YX, et al. Biophysical assessment of persistent effects of moisturizers after their daily applications: evaluation of corneotherapy. Dermatology. 2000;200:308-313. (Pubitemid 30451578)
116. Johnson AW. Overview: fundamental skin care-protecting the barrier. Dermatol Ther. 2004;17:1-5.